Revolution's on a pancreatic cancer winning streak. What comes next for the biotech? [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Revolution Medicines has been on a roll this spring, delivering a string of clinical wins that have bolstered confidence in its platform, which broadly targets the RAS mutations behind some of the deadliest cancers. Its RAS(ON) inhibitor pill, daraxonrasib, nearly doubled survival in previously treated patients with metastatic disease, while a second drug, zoldonrasib, showed early promise in hard-to-treat KRAS-driven lung cancer, shrinking tumors in more than half of patients. The company's stock prices shot up about 40% after the daraxonrasib results, helping to push its value to a heady $29 billion and crowning it as a top acquisition target But this new wave of clinical data did more than just establish Revolution as biotech's toast of the town. It also provided additional validation that RAS mutations, including KRAS, are no longer the undruggable target they once were, and that second-generation products are building on the base provided by the two approved KRAS-inhibitin
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026GlobeNewswire
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges [Yahoo! Finance]Yahoo! Finance
- Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates [Yahoo! Finance]Yahoo! Finance
- Erasca shares sink after patient death in early-stage cancer drug trial [Yahoo! Finance Canada]Yahoo! Finance Canada
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug [FOX News]FOX News
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/29/26 - Form 4
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form ARS
- RVMD's page on the SEC website